CAR-T Meeting 2025 | Cellular therapy for the treatment of autoimmune diseases: CAR-T, Tregs, and MSCs

Regarding the field of autoimmune disease, we had a great experience over the past three decades with hematopoietic stem cell transplantation, mainly autologous, that nowadays adds two standard indications. One is multiple sclerosis and the second one is systemic sclerosis. Apart from that, other immunotherapies that are growing in use are CAR T-cells from one side as we are also looking today and then mesenchymal stem cells, which have some applications in testing worldwide and also some experience in the past with T-regulatory cells, but really with limited data. So, also in this field of Tregs, we are moving to something that is coupling also the experience of CAR-T with the different cells like T-regulatory cells, so trying to make a sort of mixture of the two experiences. 

Regarding the use of mesenchymal stem cells and CAR T-cells, we are trying to provide specific guidelines within the EBMT with the publication that we have done in the past year with a multidisciplinary team coming from different societies, so it’s really a joint effort. And we try to cover both the indications with CAR-T but also with mesenchymal stem cells in the field of autoimmune disease, trying to guide the physician across all the different centers to perform that kind of treatment in the best way.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.